Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.

Trial Details

NCT ID

NCT07281924

Phase

PHASE1 / PHASE2

Sponsor

University of Wisconsin, Madison

Status

RECRUITING

Cancer Type

Melanoma

Interventions

Nivolumab and Relatlimab
Melphalan

Locations (sample)

Madison, Wisconsin, United States

Key Eligibility Criteria

Histologically or cytologically confirmed metastatic melanoma with liver metastasis (LM). Liver biopsy positive for presence of melanoma metastases…
Systemic treatment naïve in the unresectable/metastatic setting - prior adjuvant anti-programmed cell death-1 (anti-PD-1) and BRAF/MEK targeted the…
Evaluable/measurable disease according to RECIST v1.1.
Demonstrate adequate organ function; all screening labs to be obtained within 28 days prior to registration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →